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Neurobiology of Disease
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the Oligomerization of Amyloid ␤ Peptide
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Adrian Olaf Banerji,1 Akinori Mitani,1 Daniel Joyner,1 Diana H. Thyssen,1 Brian J. Bacskai,1 Matthew P. Frosch,1
Tara L. Spires-Jones,1 Mary Beth Finn,2 David M. Holtzman,2 and Bradley T. Hyman1
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1

Alzheimer’s disease (AD) is the most common progressive neurodegenerative disorder causing dementia. Massive deposition of amyloid
␤ peptide (A␤) as senile plaques in the brain is the pathological hallmark of AD, but oligomeric, soluble forms of A␤ have been implicated
as the synaptotoxic component. The apolipoprotein E  4 (apoE 4) allele is known to be a genetic risk factor for developing AD. However,
it is still unknown how apoE impacts the process of A␤ oligomerization. Here, we found that the level of A␤ oligomers in APOE 4/4 AD
patient brains is 2.7 times higher than those in APOE 3/3 AD patient brains, matched for total plaque burden, suggesting that apoE4
impacts the metabolism of A␤ oligomers. To test this hypothesis, we examined the effect of apoE on A␤ oligomer formation. Using both
synthetic A␤ and a split-luciferase method for monitoring A␤ oligomers, we observed that apoE increased the level of A␤ oligomers in an
isoform-dependent manner (E2 ⬍ E3 ⬍ E4). This effect appears to be dependent on the ApoE C-terminal domain. Moreover, these results
were confirmed using endogenous apoE isolated from the TBS-soluble fraction of human brain, which increased the formation of A␤
oligomers. Together, these data show that lipidated apoE, especially apoE4, increases A␤ oligomers in the brain. Higher levels of A␤
oligomers in the brains of APOE 4/4 carriers compared with APOE 3/3 carriers may increase the loss of dendritic spines and
accelerate memory impairments, leading to earlier cognitive decline in AD.

Introduction
The hallmark of Alzheimer’s disease (AD) is deposition of fibrillar amyloid ␤ peptide (A␤) in senile plaques in the brain (Selkoe,
2001; Holtzman et al., 2011). Recent data, however, suggest that
instead of, or in addition to, plaques, soluble oligomeric forms of
A␤ are crucial for synaptic dysfunction, cognitive impairment
and neurodegeneration (Lesné et al., 2006; Shankar et al., 2008;
Koffie et al., 2009; Wu et al., 2010). However, it is still unknown
what factors influence the kinetics of formation of soluble A␤
oligomers.
Apolipoprotein E (apoE) is a known A␤ binding protein and
is a genetic risk factor for AD (Bu, 2009). There are 3 common
alleles of the human APOE gene 2, 3, and 4 (Zannis et al.,
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ated with a ⬎10-fold increased risk for developing AD compared
with the most common APOE 3/3 genotype (Corder et al.,
1993; Strittmatter et al., 1993a). However, the mechanisms
whereby APOE 4 promotes the development of AD remain controversial. There is strong evidence that apoE, and particularly
apoE4, facilitates amyloid fibril deposition. Senile plaque density
in the brains of APOE 4/4 carrier AD patients is significantly
higher than that in the brains of APOE 3/3 carrier AD patients
(Rebeck et al., 1993; Gomez-Isla et al., 1996). apoE-deficient mice
crossed with APP (amyloid precursor protein)-transgenic mice
exhibited a decrease in amyloid deposition in the brain, and human apoE4 overexpression increased fibrillar A␤ deposits compared with human apoE3 (Holtzman et al., 2000; Fagan et al.,
2002). Moreover, recent studies support a role of apoE in A␤
metabolism. Using an in vivo microdialysis technique, the halflife of A␤ in the brain of apoE knock-out mice markedly decreased compared with wild-type mice (DeMattos et al., 2004).
Importantly, it has now been shown that in APP-transgenic mice
expressing apoE2, E3, and E4, apoE4 significantly slows A␤ clearance relative to E2 and E3 but has no effect on A␤ synthesis
(Castellano et al., 2011).
Previous studies have revealed that apoE interacts with A␤ in
vitro (Strittmatter et al., 1993b; LaDu et al., 1994) and in vivo,
both in the CSF (Strittmatter et al., 1993a) and in the brain (Näslund et al., 1995). However, because of the difficulty in monitoring A␤ oligomers specifically and quantitatively, whether apoE
increases the levels of native A␤ oligomers remains unknown. In
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this study we hypothesize that apoE, especially apoE4, impacts
the formation of A␤ oligomers. We observed significantly increased levels of A␤ oligomers in APOE 4/4 AD patient brains
compared with APOE 2/x or APOE 3/3 AD patient brains.
We also found that apoE4 enhances the level of A␤ oligomers,
using a split-luciferase complementation assay that enables
quantitative monitoring of the formation of A␤ oligomers. Furthermore, endogenous apoE from human brain also increased
the level of A␤ oligomers in vitro. These data suggest that apoE,
especially apoE4, impacts A␤ oligomer levels by enhancing their
formation and stabilizing them once formed.

Materials and Methods
Brain extraction and gel filtration. Brains from human subjects with a
diagnosis of Alzheimer’s disease or no cognitive deficits were obtained
through the Massachusetts Alzheimer’s Disease Research Center. Cases
were selected to have equivalent amyloid load (Ingelsson et al., 2004) and
to be either APOE 2/x, APOE 3/3, or APOE 4/4; these data were
not revealed during subsequent biochemical assays. The case number is 8
in control (4 males and 4 females), 6 in APOE 2/x AD (6 females), 10 in
APOE 3/3 AD (4 males and 6 females) or 10 in APOE 4/4 AD (5
males and 5 females). Cortical gray matter from frontal lobe of AD patient brains or non-demented control brains was homogenized in 5 volumes of TBSI (Tris-buffered saline with Protease Inhibitor Cocktail;
Roche) with 25 strokes on a mechanical Dounce homogenizer and centrifuged at 260,000 ⫻ g for 30 min at 4°C. The supernatant was used as a
TBS-soluble fraction (Hashimoto et al., 2002). TBS-soluble fraction (750
l) of human brains was separated by size-exclusion chromatography
(SEC) on single or double Superdex 75 columns (GE Healthcare) in 50
mM ammonium acetate, pH 8.5, with an AKTA purifier 10 (GE Healthcare; Townsend et al., 2006). Conditioned medium from HEK293 cells
(750 l) was separated by size exclusion chromatography on a Superdex
200 column (GE Healthcare) in 50 mM ammonium acetate, pH 8.5, with
an AKTA purifier 10 (GE Healthcare). The individual fractions separated
by SEC were analyzed by immunoblotting and A␤-specific sandwich
ELISA.
cDNA plasmids. Human ApoE2, ApoE3, and ApoE4 genes were a gift
from Dr. Mary Jo LaDu at University of Illinois at Chicago. The human
ApoA-I gene was purchased from the full-length mammalian gene collection (Invitrogen) and subcloned into pcDNA3.1 vector (Invitrogen)
between HindIII site and BamHI site using the following primers: 5⬘-GA
GAAGAAGCTTCCCCACGGCCCTTCAGG-3⬘ (forward), 5⬘-ATTC
TGGGATCCGGGAAGGGGGGCGGCGG-3⬘ (reverse). The human
ApoA-II gene was also purchased from the full-length mammalian gene
collection and subcloned into pcDNA3.1 vector between HindIII site and
BamHI site using the following primers: 5⬘-ACAGAGAAGCTTGCTA
GGCCGCCCTCCCC-3⬘(forward),5⬘-GGGACAGGATCCCTAGGACT
GGCCAGTGGG-3⬘ (reverse). The human ApoJ/clusterin gene was
purchased from the full-length mammalian gene collection and subcloned into pcDNA3.1 vector between HindIII site and BamHI site using
the following primers: 5⬘-TGACCGAAGCTTGCAAAGACTCCAGAAT
TGG-3⬘ (forward), 5⬘-AGTGCAGGATCCAGAGCGGGGAGAGG-3⬘
(reverse). For the apoE4 R61T mutant, we mutated Arg61 of apoE4
cDNA plasmid into Thr by in vitro site-directed mutagenesis using the
following primers: 5⬘-CACCCAGGAGCTCACGGCGCTGATGG-3⬘
(forward), 5⬘-CCATCAGCGCCGTGAGCTCCTGGGTG-3⬘ (reverse).
For the N-terminal fragments of apoE (apoE2 NTF, apoE3 NTF, and
apoE4 NTF), we deleted apoE192–299 from the apoE2, apoE3, and
apoE4 cDNA plasmids, respectively, using the following primers: 5⬘-TG
AACGCCGAAGCCTGCAGCCATGCG-3⬘ (apoE1–191 forward), 5⬘-CC
GCACGCGGCCCTGTTCCACCAGGGG-3⬘ (apoE1–191 reverse). For
the C-terminal fragment of apoE (apoE CTF), we deleted apoE1–191
from the apoE2 cDNA plasmid using the following primers: 5⬘-GCCG
CCACTGTGGGCTCCCTGGCC-3⬘ (apoE192–299 forward), 5⬘-CTTG
GCCTGGCATCCTGCCAGGAATGTG-3⬘ (apoE192–299 reverse). The
apoE signal sequence was retained before the apoE CTF. For the
apoE231–299, we deleted apoE192–230 from the apoE CTF cDNA plasmid using the following primers: 5⬘-GAGGTGAAGGAGCAGGTGGC
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GGAGG-3⬘ (apoE231–299 forward) and apoE192–299 reverse primer.
For apoE243–299, we deleted apoE192–242 from the apoE CTF cDNA
plasmid using the following primers: 5⬘-CTGGAGGAGCAGGCCCAG
CAGATACGCC-3⬘ (apoE243–299 forward) and apoE192–299 reverse
primer. For apoE192–272, we deleted apoE273–299 from the apoE CTF
cDNA plasmid using the following primers: apoE1–191 forward primer
and 5⬘-CATGTCTTCCACCAGGGGCTCGAACC-3⬘ (apoE192–272 reverse). For apoE192–242, we deleted apoE243–299 from the apoE CTF
cDNA plasmid using the following primers: apoE1–191 forward primer
and 5⬘-CTTGGCGCGCACCTCCGCCACCTGC-3⬘ (apoE192–242 reverse). For apoE3 ⌬243–272, we deleted apoE243–272 from the apoE3
cDNA plasmid using the following primers: 5⬘-CAGCGCCAGTGGGC
CGGGCTGGTGG-3⬘ (apoE273–299 forward) and apoE192–242 reverse
primer. For apoE3⌬273–299, we deleted apoE273–299 from the apoE3
cDNA plasmid using the following primers: apoE1–191 forward primer
and apoE192–272 reverse primer. For apoE3⌬243–299, we deleted
apoE243–299 from the apoE3 cDNA plasmid using the following primers: apoE1–191 forward primer and apoE192–242 reverse primer.
Cell culture and transient transfection. Both N-terminal and C-terminal
fragments of split-luciferase-tagged A␤ stably overexpressing HEK293
cells (doubly expressing HEK293 cells) were generated previously
(Hashimoto et al., 2011). Doubly expressing HEK293 cells were cultured
in Opti-MEM (Invitrogen) with 10% fetal bovine serum at 37°C in 5%
CO2 atmosphere. Transient apoEs or apoE mutants expressing cell lines
were generated by transfecting cDNA plasmids using Lipofectamine
2000 (Invitrogen) as suggested by the manufacturer. For luciferase assays
of the conditioned medium, we incubated HEK293 cells 24 h after transfection, changed the medium to Opti-MEM without fetal bovine serum
for 24 h at 37°C in 5% CO2 atmosphere, and collected conditioned medium. For luciferase assays of the cell lysate, we washed the cells with PBS
and harvested them with Lysis Buffer (Promega).
Immunoblotting, sandwich ELISA, immunodepletion, immunoprecipitation. Brain TBS-soluble fractions, individual SEC fractions or conditioned media from HEK293 cells were electrophoresed on 10 –20% or
4 –20% Novex Tris-Glycine gels (Invitrogen) in Tris-Glycine SDS running buffer for SDS-PAGE (Invitrogen). Gels were transferred to a polyvinylidene difluoride membrane (PolyScreen, PerkinElmer), and
blocked for 30 min at room temperature (RT) in 5% nonfat skim milk/
TBST (Tris-buffer saline with 0.1% Tween 20). Membranes were probed
with 1 g/ml monoclonal anti-A␤ antibody 6E10 (Signet) or 82E1 (IBL
International), anti-apoE antibody 6C5 (Ottawa Heart Institute), or 3H1
(Ottawa Heart Institute) in TBST for 2 h at RT or for 12 h at 4°C.
Following incubation with horseradish peroxidase-conjugated secondary antibody (Bio-Rad) for 1 h at RT, immunoreactive proteins were
developed using an ECL kit (Western Lightning, PerkinElmer) and detected on Hyperfilm ECL (GE Healthcare; Jones et al., 2011). For the
A␤40 and A␤42 quantification, individual SEC fractions were diluted
and subjected to BNT77/BA27 for A␤40, or BNT77/BC05 for A␤42 using
two-site ELISAs (WAKO Chemicals) and quantified as suggested by the
manufacturer. For guanidine treatment, individual SEC fractions were
incubated with 8 M guanidine-HCl (concentration of guanidine-HCl in
the sample is 4 M) for 30 min at room temperature, diluted by 7 volumes
of standard dilution buffer (final concentration of guanidine-HCl in the
sample is 0.5 M) and subjected to ELISA (Yamada et al., 2009). For immunodepletion, we first incubated 200 l of SEC-separated fractions
with 30 l of protein G magnetic beads (Millipore) for 1 h at 4°C and
removed beads by using a magnet. We next incubated supernatants with
or without 5 g of anti-human apoE mAb 3H1 or anti-ApoA-I mAb 4H1
(Ottawa Heart Institute) for 12 h at 4°C. We further incubated samples
with 30 l of protein G magnetic beads for 2 h at 4°C, removed beads by
using a magnet, and collected the supernatant as immunodepleted samples. For immunoprecipitation, we first incubated 200 l of SECseparated fractions with 30 l of protein-G Sepharose beads (Invitrogen)
for 1 h at 4°C and removed beads by centrifugation at 8000 rpm for 5 min
at 4°C. The supernatants were incubated with anti-apoE (Millipore, Calbiochem), anti-A␤ (6E10), or control Ig (anti-p-glycoprotein) for 8 h at
4°C. Incubated samples were centrifuged at 8000 rpm for 5 min at 4°C
and the pellets were washed by TBST 2 times, incubated with sample
buffer for 10 min at 95°C, and applied to SDS-polyacrylamide gels.
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Table 1. Information about the cases used in this study
a

Control
AD (⑀2/⑀x)b
AD (⑀3/⑀3)
AD (⑀4/⑀4)
p valuec

Number

Age at death (years)

Gender, n (% female)

Disease duration (years)

Postmortem interval (hours)

8
6
10
10
NA

77.7 ⫾ 10.5
78.8 ⫾ 8.7
78.7 ⫾ 10.5
78.5 ⫾ 8.0
0.9977

4 (50.0)
6 (100.0)
6 (60.0)
5 (50.0)
0.8994

NA
11.7 ⫾ 5.2
11.7 ⫾ 4.7
13.6 ⫾ 4.6
0.9830

24.3 ⫾ 22.1
20.0 ⫾ 7.1
14.7 ⫾ 8.0
19.6 ⫾ 19.0
0.6968

a

Of these individuals, n ⫽ 2 (⑀2/⑀3), n ⫽ 5 (⑀3/⑀3), n ⫽ 1 (⑀3/⑀4).
Of these individuals, n ⫽ 1 (⑀2/⑀2), n ⫽ 2 (⑀2/⑀3), n ⫽ 3 (⑀2/⑀4).
c
One-way Kruskal–Wallis ANOVA, except for gender, which was analyzed using 2 test. Postmortem interval was not available for 2 controls and 1 AD (⑀2/⑀x) subject.
NA, Not applicable.
b

Statistical analysis was performed by one-way ANOVA using Prism 5
for Mac OSX (GraphPad). Following ANOVA, Bonferroni’s or Tukey’s
post hoc test was applied.
A␤ Immunohistochemistry and amyloid burden analysis. Eight-micrometerthick paraffin-embedded sections from the frontal association cortex (Brodmann’s area 8,9) were obtained from the Massachusetts General Hospital
Alzheimer Disease Research Center Brain Bank. Sections were deparaffinized with xylenes, rinsed in H2O2 0.3% in methanol for 20 min to block
the endogenous peroxidase activity, and hydrated with decreasing concentrations of ethanol. Antigen retrieval before immunostaining was achieved
by microwaving the sections in citrate buffer (0.01 M citric acid anhydrous,
Tris-buffered saline, 0.05% Tween 20, NaOH to pH 6.0) at 95°C for 20 min,
followed by a rinse in formic acid 90% for 5 min. After extensive washing,
sections were blocked with 5% nonfat milk for 1 h to avoid nonspecific
binding of the primary antibody. Sections were incubated overnight at
4°C with the N-terminal-specific anti-A␤ 10D5 mouse monoclonal
antibody (1:50, Elan Pharmaceuticals). On the next day, sections were
thoroughly washed, incubated with a goat anti-mouse-HRP-linked secondary antibody (1:200, Jackson ImmunoResearch) for 2 h at room temperature, and developed with 3–3⬘-diaminobenzidine. Finally, sections were
lightly counterstained with Mayer’s hematoxylin, dehydrated with increasing concentrations of ethanol, cleared with xylenes, and coverslipped with
Permount mounting medium (Fisher Scientific).
The amyloid plaque burden (or amyloid load) was measured as the
percentage of total cortical surface occupied by amyloid plaques. Plaque
burden analysis was performed using the BIOQUANT system. Briefly,
sections were placed on the motorized stage of an upright Leica DMRB
microscope that was equipped with a CCD camera (model DC330,
DAGE-MT) and coupled with BIOQUANT Nova Prime software (version 6.90.10.MBSR). An ⬇1-cm-long strip of full-depth cortex was outlined under the 1.6⫻ objective and amyloid plaques were thresholded
under the 10⫻ objective using the appropriate tool of the software (Ingelsson et al., 2004).
Purification of apoE from immortalized astrocytes. Lipidated apoE
particles were purified from culture media of human apoE2-, apoE3-,
or apoE4-overexpressing immortalized astrocytes using an affinity
column as described previously (Morikawa et al., 2005). Briefly, astrocytes were cultured in advanced DMEM (Invitrogen) with 10%
FBS. After 90 –95% confluency, cells were washed by PBS and further
incubated in advanced DMEM with N-2 Supplement (Invitrogen)
and 3 mM 25-hydroxycholesterol (Sigma) during 2⬃3 d. Collected
culture media were applied onto mouse monoclonal antibody against
a human apoE (WU E-4) column. Lipidated apoE particles were
eluted from the column with 3 M sodium thiocyanate, concentrated
using Apollo centrifugal quantitative concentrators (QMWL: 150
kDa, Orbital Biosciences), and dialyzed against PBS.
In vitro A␤ oligomerization assay. We incubated 0.1 mg/ml synthetic
A␤1– 42 (Peptides International) with or without 10 g of purified
apoE2, apoE3, or apoE4 particles at 4°C for 0, 1.5, 6, 12, and 24 h and
immediately applied the solution to SDS-PAGE (Hori et al., 2007).
Split-luciferase complementation assay. HEK293 cells were stably transfected with two plasmids, each containing a complementary splitluciferase assay for A␤ oligomerization, as we have recently described
(Hashimoto et al., 2011). Conditioned media from these cells were collected and centrifuged at 1200 rpm for 5 min to remove cell debris. After
adding 17 g/ml coelenterazine (NanoLight Technology) diluted by

Opti-MEM into samples, luciferase activity was immediately measured
using a Wallac 1420 (PerkinElmer) plate reader.
Statistical analysis was performed by one-way ANOVA using Prism 5
for Mac OSX (GraphPad). Following ANOVA, Bonferroni’s post hoc test
is applied.

Results

APOE 4/4 AD patients have higher levels of A␤ oligomers
in their brain than do APOE 3/3 or APOE 2/x AD
patients
To investigate the effect of the different apoE isoforms on the
metabolism of A␤ oligomers, we extracted the TBS-soluble fraction from the frontal associative neocortices of 8 non-demented
controls, 6 AD patients with the APOE 2/x genotype, 10 AD
patients with the APOE 3/3 genotype, and 10 AD patients with
the APOE 4/4 genotype (Table 1). Because it is known that the
level of senile plaque density in APOE 4/4 carrier AD is on
average significantly higher than that in APOE 3/3 carrier AD
(Rebeck et al., 1993), we carefully selected brains to have equal
amyloid load in an adjacent cortical region by an immunohistochemical analysis using anti-A␤ antibody 10D5 (3.7 ⫾ 1.4% in
APOE 2/x AD patients, 3.0 ⫾ 1.3% in APOE 3/3 AD patients
and 3.4 ⫾ 2.1% in APOE 4/4 AD patients, no significant difference; Fig. 1C). Selected brains also had a similar age at death,
gender ratio, disease duration, and postmortem interval (Table
1). An equal amount of the TBS-soluble proteins from each of
these brains was applied to SDS-polyacrylamide gels and visualized by anti-human A␤-specific antibody 82E1 (Fig. 1 A). While
no bands were detectable in the TBS-soluble fraction from control brains, a 4 kDa band, corresponding (under these denaturing
conditions) to monomeric A␤, was observed in the TBS-soluble
fraction from both APOE 3/3 AD patient brains and APOE
4/4 AD patient brains. We also detected an 8 kDa band corresponding to SDS-stable A␤ dimers, in the TBS-soluble fraction
from several APOE 4/4 AD patient brains. To quantitate the
concentration of A␤, we applied synthetic A␤1– 42 with known
concentrations to the same gels and determined the concentration of A␤ in each TBS-soluble fraction. Despite the AD groups
being matched for amyloid plaque burden (Fig. 1C), the level of
TBS-soluble A␤ in APOE 4/4 AD patient brains was 2.7 times
higher than that in APOE 3/3 AD patient brains, 6.9 times
higher than that in APOE 2/x AD patient brains, and substantially times higher than the barely control brains’ detectable levels
(2.7 ⫾ 5.0 g/g brain lysate in control, 57.8 ⫾ 54.6 g/g brain
lysate in APOE 2/X, 144.7 ⫾ 185.8 g/g brain lysate in APOE
3/3 AD patient, and 396.9 ⫾ 315.0 g/g brain lysate in APOE
4/4 AD patients; p ⬍ 0.05, 4/4 vs 3/3; p ⬍ 0.01, 4/4 vs
2/x, control, 3/3 vs control; Fig. 1 B). We compared the
amount of total soluble A␤ with the histochemically defined
amounts of amyloid deposited in senile plaques, and found no
correlation between plaque burden and levels of soluble A␤ (Fig.
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Figure 1. The level of A␤ oligomers in the brain of APOE 4/4 AD patients was significantly higher compared with APOE 3/3 AD patients. A, Immunoblotting of 50 g of TBS-soluble fractions
from 4 control, 5 APOE 3/3 AD, and 5 APOE 4/4 AD prefrontal brains. An anti-A␤ mAb 82E1 revealed A␤ monomers (arrow) and dimers (arrowhead). B, Quantification of TBS-soluble A␤ from
8 control (white squares), 6 APOE 2/x AD (dark squares), 10 APOE 3/3 AD (dark triangles), and 10 APOE 4/4 AD brains (black circles). The level of A␤ in APOE 4/4 AD brains was significantly
higher compared with control brains, APOE 2/x AD brains, and APOE 3/3 AD brains. *p ⬍ 0.05, **p ⬍ 0.01, one-way ANOVA test (Tukey’s post hoc test). C, Amyloid burden (%) in the prefrontal
cortex of 8 control (white squares), 6 APOE 2/x AD (dark squares), 10 APOE 3/3 AD (dark triangles), and 10 APOE 4/4 AD brains (black circles) analyzed in this study. There is no significant
difference among APOE 2/x AD, between APOE 3/3 AD and APOE 4/4 AD brains, one-way ANOVA test (Kruskal–Wallis test). D, Correlation analysis between the level TBS-soluble A␤ and
the level of A␤ amyloid burden in 6 APOE 2/x AD (dark squares), 10 APOE 3/3 AD (dark triangles), and 10 APOE 4/4 AD brains (black circles). There is no significant difference. E,
Quantification of apoE concentration in the TBS-soluble fraction of 8 control (white squares), 6 APOE 2/x AD (dark squares), 10 APOE 3/3 AD (dark triangles), and 10 APOE 4/4 AD brains (black
circles). F, Immunoblotting of SEC-separated fractions from APOE 4/4 AD brain. Anti-A␤ mAb 82E1 and 6E10 revealed A␤ (arrow) and sAPP␣ (arrowhead). A␤ eluted from 94 kDa to 217 kDa as
HMW A␤ and eluted from 8.6 to 16 kDa as LMW A␤. Estimated molecular weight (kDa) was indicated above (arrowheads). G, Representative data of the separation of 200 mg of TBS-soluble fractions
of APOE 3/3 AD (triangles) and APOE 4/4 AD (squares) brains by double Superdex 75 SEC columns. The concentration of A␤40 is measured by A␤ specific ELISA (BNT77-BA27) (Wako).
Estimated molecular weight (kDa) was indicated above (arrowheads). A␤ in TBS-soluble fraction formed dimer, trimer and HMW oligomers.

1 D, r ⫽ ⫺0.01, p ⫽ 0.95). This suggests that the amount of
TBS-soluble A␤ is independent of the amount of deposited amyloid plaques.
It has also been reported that the level of apoE protein in the
brains of APOE 4/4 carriers is smaller than that of APOE 3/3

AD carriers or of APOE 2/2 carriers (Riddell et al., 2008). We
measured the concentration of apoE in TBS-soluble fraction
from the brains of control and AD cases by specific ELISA and
found that it is similar among control and AD cases regardless of
genotypes (Fig. 1 E).
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these results and further refine this characterization, we applied the TBS-soluble
fractions from 3 APOE 3/3 and 6 APOE
4/4 AD patients’ brains onto two (tandem) Superdex 75 SEC columns, collected
the eluted fractions, and measured the
concentration of A␤ by an A␤-specific
ELISA (Fig. 1G). Similar to the result of
immunoblotting above (Fig. 1 E), we
found that A␤ eluted into fractions from
100 to 200 kDa as HMW A␤, fractions
around 90 kDa, fractions around 30 kDa,
and fractions from 6 to 20 kDa (the latter
LMW A␤, likely reflecting A␤ dimers and
A␤ trimers). Remarkably, we found that
the TBS-soluble fraction from APOE
4/4 AD patient brains exhibited substantially higher amounts of A␤ in every
peak compared with APOE 3/3 AD patient brains. Together, the level of TBSsoluble A␤ oligomers in APOE 4/4 AD
patient brains was significantly higher
than that in APOE 3/3 AD patient
brains.
ApoE forms HMW complex with A␤
oligomers in the brains of AD patients
Compared with immunoblotting results
(Fig. 1 F), we did not detect a strong signal
of A␤ in HMW A␤ fractions by ELISA
(Fig. 1G). We postulated that the structure of highly oligomeric A␤ may inhibit
the interaction between A␤ and anti-A␤
antibodies, or unidentified interacting
molecules with A␤ in the HMW fraction
may interfere with the detection of A␤ by
anti-A␤ antibodies used in the ELISA. To
examine these possibilities, we incubated
individual SEC fractions with or without 8
M guanidine-HCl for 30 min and quantified A␤ concentration by ELISA. We
found that the measured concentration of
Figure 2. apoE forms HMW complex with A␤ oligomers in the brains of AD patients. A, Representative data from guanidine-HCl A␤ in HMW fractions dramatically intreatment for SEC-separated fractions. SEC-separated fractions from 5 to 11, from 29 to 34 were incubated with (black) or without creased, while the levels of A␤ in LMW
(white) 8 M guanidine HCl and quantified the A␤ concentration by specific ELISA (BNT77-BA27). B, Immunoblotting of SEC- fractions exhibited no difference (Fig.
separated fractions (fraction 3–12) from an APOE 4/4 AD brain. Top, Anti-mAbs 82E1 and 6E10 revealed A␤ monomers (arrow), 2 A), consistent with the idea that epitopes
dimers, and sAPP␣ (arrowhead). Bottom, Anti-mAb 3H1 revealed apoE (arrow). Estimated molecular weight (kDa) is indicated were masked in the HMW fraction.
above (arrowheads). C, Immunoprecipitation using anti-apoE antibodies and control antibody from SEC-separated fraction 8 and
ApoE is secreted in high-density lipoimmunoblotted by an anti-A␤ mAb 82E1. A␤ monomers and dimmers were detected (arrows).
protein (HDL) particles in the brain. To
know whether apoE interacts with TBSThe finding of SDS-stable A␤ dimers in the TBS-soluble fracsoluble A␤ oligomers and contributes to their apparent HMW,
tion of some APOE 4/4 AD patients brains (Fig. 1 A) prompted
we immunoprobed A␤ and apoE protein in each SEC-separated
us to further characterize the presence of TBS-soluble A␤ olifraction of TBS-soluble fraction from APOE 4/4 AD patient
gomers under native conditions. We separated TBS-soluble fracbrain using anti-A␤ and anti-apoE antibodies on SDStions by SEC. We applied the TBS-soluble fraction of APOE 4/4
polyacrylamide gels (Fig. 2 B). We found that A␤ and apoE eluted
AD patient brain onto two (tandem) Superdex 75 SEC columns
in identical fractions, ranging from 185 to 256 kDa, suggesting
(Townsend et al., 2006), collected fractions, applied the fractions
that HMW A␤ may interact with apoE on the HDL particles. We
into SDS-polyacrylamide gels, and detected A␤ by the antialso detected HMW A␤ and apoE in similar fractions from 185 to
human A␤ antibody 6E10 (Fig. 1 F). We found that fractions
256 kDa using SEC-separated samples from the TBS-soluble fraceluting from 94 kDa to 217 kDa strongly exhibited 4 kDa A␤
tion of an APOE 3/3 AD patient brain. Immunoprecipitation
[hereafter called high-molecular weight (HMW) A␤] and fracof apoE using each of two separate polyclonal antibodies (antitions eluting from 8.6 kDa to 16 kDa also exhibited 4 kDa A␤
apoE Ig, Calbiochem; and anti-apoE Ig, Millipore) pulled down
[hereafter called low-molecular weight (LMW) A␤]. To confirm
A␤ from these fractions (Fig. 2C). These data suggest that apoE
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interacts with A␤ oligomers in human AD
brain and thus may impact their oligomerization in the brain.
Purified apoE on HDL particles
enhances synthetic A␤1– 42 oligomer
formation in vitro
We hypothesized that apoE on HDL particles would affect the A␤ oligomerization in
the brain in an isoform-dependent manner.
In an in vitro A␤ fibrillization assay, apoE is
known to inhibit A␤ fibrillization especially
in the seeding phase of A␤ fibrillization (Evans et al., 1995; Naiki et al., 1997). Because
these experiments used recombinant nonlipidated apoE and because they evaluated
the level of A␤ fibrillization using the thioflavin T dye, which specifically interacts with
␤-sheeted structures but not oligomers, we
reevaluated this interaction using physiologically relevant lipids and synthetic A␤.
We purified apoE lipid particles from immortalized astrocyte cell lines derived from
human apoE2, apoE3, or apoE4 knock-in
mice. These immortalized astrocyte cells
are known to secrete human apoEs in
HDL-like particles into conditioned media (Morikawa et al., 2005). We incubated
0.1 mg/ml (⬃22 M) synthetic A␤1–42 with
or without 10 g of purified lipidated apoE2,
apoE3, or apoE4 at 4°C for 0, 1.5, 6, 12, or 24 h
in vitro and applied the samples to SDSpolyacrylamide gels (Fig. 3A). In the absence
of apoE, the A␤ trimers and A␤ tetramers dis- Figure 3. Purified apoE-containing HDL particles enhanced oligomer formation of synthetic A␤1– 42 in vitro. A, Immunoblotappeared within 6 h and were replaced by ting for A␤ after incubation of 0.1 mg/ml synthetic A␤1– 42 with PBS, 10 g of purified apoE2, 10 g of apoE3, or 10 g of apoE4
smear bands after 6 h (Fig. 3A, PBS panel). In for the indicated times (hours). Anti-A␤ mAb 6E10 revealed A␤ monomer, dimer, trimer, and tetramer (arrows). B, Band intensity
contrast, in the presence of lipidated apoE2, of remaining A␤ in SDS-polyacrylamide gels after incubation of synthetic A␤1– 42 oligomers with PBS (no), 5 g/ml purified
apoE3,orapoE4,thebandsforA␤ trimersand lipidated apoE2, apoE3, or apoE4 for 12 h using an anti-A␤ mAb 6E10. Lipidated apoE4 significantly increased the level of A␤
A␤ tetramers gradually accumulated during trimer and tetramer compared with no lipidated apoE samples. N ⫽ 6, average ⫾ SD, *p ⬍ 0.05, one-way ANOVA test (Bonferroni’s test). C, Luminescence from conditioned media containing split-luciferase-tagged A␤ oligomers incubated with 0, 0.1, 0.3,
the incubation period (Fig. 3A, apoE2, apoE3, 0.6, 1.25, 2.5, 5, or 10 g of purified apoE2 (lipid apoE2, squares), purified apoE3 (lipid apoE3, triangles), or purified apoE4 (lipid
apoE4 panels). Of note, qualitative inspection apoE4, circles) for 24 h. N ⫽ 6, average ⫾ SD, *p ⬍ 0.05, one-way ANOVA test (Bonferroni’s test). D, Incubation of LMW A␤
of the gels show that incubation of A␤ with isolated from TBS-soluble fractions of the AD brains with (apoE) or without (PBS) 5 g of purified lipid apoE3 and separated the
apoE3 or apoE4 yielded higher levels of A␤ samples by double Superdex 75 SEC columns. The concentration of A␤40 was measured by A␤-specific ELISA (BNT77-BA27, WAKO
trimers and A␤ tetramers than incubation Chemicals) and obtained the ratio of HMW A␤ measured (in fraction 7 and 8). N ⫽ 4, average ⫾ SD, *p ⬍ 0.05, student’ t test.
with apoE2. This result may suggest that lipidated apoE enhanced the oligomerization of
luminescence. Once split-luciferase-tagged A␤ forms oligomers, the
A␤ or stabilized the A␤ oligomers. To elucidate whether lipidated apoE
N- and C-terminal fragments of luciferase reconstitute into a funcstabilize A␤ oligomers, we incubated synthetic A␤1–42 oligomers with
tional molecule that exhibits luminescence (Hashimoto et al., 2011).
5 g/ml lipidated apoE2, apoE3, or apoE4 for 12 h in vitro, applied the
This technique has the advantage of monitoring A␤ oligomers spesamples to SDS-polyacrylamide gels, and quantified the level of remaincifically and quantitatively without background from monomers.
ing A␤ oligomers (Fig. 3B). Lipidated apoE4 significantly increased the
We incubated split-luciferase-tagged A␤ oligomers with 0, 0.1, 0.3,
level of A␤ trimers and tetramers compared with the sample incubated
0.6, 1.25, 2.5, 5, and 10 g of purified lipidated apoE2, apoE3, or
without apoE (130.0 ⫾ 19.0% in trimers and 235.3 ⫾ 85.4% in tetramapoE4 for 24 h and measured the luminescence (Fig. 3C). We found
ers), suggesting that apoE4 may stabilize the A␤ oligomers. On the other
that purified lipidated apoE in a dose-dependent manner enhanced
hand, lipidated apoE2 and apoE3 did not exhibit significant increase of
the level of A␤ oligomers in an isoform-dependent manner
the level of the A␤ oligomers (Fig. 3B).
(apoE2
⬍ apoE3 ⬍ apoE4). Moreover, we isolated LMW A␤ from
Because the concentration of A␤ oligomers is quite small, it is diffiTBS-soluble
fraction of the brains of APOE 4/4 AD patients by
cult to quantitatively monitor A␤ oligomers using these techniques. To
SEC,
incubated
with or without 5 g of purified lipidated apoE3,
evaluate the role of apoE in the formation of A␤ oligomers, we took
applied to two (tandem) Superdex 75 SEC columns again, and quanadvantage of a recently developed method using a split-luciferase
tified the level of A␤ by the specific ELISA. We found that after
complementation assay (Hashimoto et al., 2011). In this assay, the
incubation with purified lipidated apoE, ⬃6.5% of LMW A␤ instead
N- and C-terminal fragments of Gaussia luciferase are fused sepaelutes in the HMW A␤ fraction (Fig. 3D, 6.5 ⫾ 0.3% with apoE,
rately to A␤, so that single split-luciferase-tagged A␤ does not exhibit
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0.5 ⫾ 0.7 without apoE), an increase of over tenfold. These qualitative and quantitative data suggest that lipidated apoE enhances A␤
oligomerization and inhibited further aggregation in vitro.
apoE enhances the level of A␤ oligomers in an isoformdependent manner (apoE2 < apoE3 < apoE4)
Using the split-luciferase complementation assay for monitoring A␤ oligomers, we further examined apoE’s effect on A␤
oligomers. First we transiently transfected apoA-II, apoE2,
apoE3, and apoE4 into doubly expressing HEK293 cells stably
expressing both N- and C-terminal fragments of luciferasetagged A␤, collected their conditioned media after 24 h of
incubation, and measured A␤ oligomers by measuring luminescence in the media (Fig. 4 A, B). We found that apoE2,
apoE3, or apoE4 each increased the luminescence. On the
other hand, apoA-II, one of the other apolipoproteins in brain
HDL particles, did not change the luminescence compared
with GFP transfection (91.8 ⫾ 5.1% in apoA-II, 200.3 ⫾
10.2% in apoE2, 275.5 ⫾ 15.0% in apoE3, 338.1 ⫾ 18.5% in
apoE4; p ⬍ 0.05, E2 vs E3; E3 vs E4). apoA-II was therefore
used as a control transfection for subsequent experiments.
apoE4 significantly increased the luminescence to a greater
extent than apoE2 and apoE3, and apoE3 significantly increased the luminescence to a greater extent than apoE2, suggesting that apoE enhanced the level of A␤ oligomers in an
isoform-dependent manner (apoE2 ⬍ apoE3 ⬍ apoE4). We
did not see any difference in the levels of apoE in the conditioned media (Fig. 4 B).
Although HEK293 cells transfected with human apoE3 and
apoE4 naturally secrete apoE lipoparticles into the culture media
(LaDu et al., 2006), we asked whether the induction of A␤ oligomerization by apoE might actually be taking place within the
cells, before the secretion of apoE to the conditioned media. To
test this, we transfected apoA-II, apoE2, apoE3, and apoE4 into
doubly expressing HEK293 cells, collected cell lysates after 24 h
incubation and measured the luminescence in cell lysates (Fig.
4C). We found that apoE2, apoE3, and apoE4 did not enhance
the luminescence within cell lysates (100.0 ⫾ 12.7% in apoA-II,
89.9 ⫾ 9.7% in apoE2, 96.4 ⫾ 13.9% in apoE3, 92.5 ⫾ 2.2% in
apoE4, no significant difference). Nevertheless they strongly increased the luminescence in the conditioned media (Fig. 4 A),
suggesting that apoE influences A␤ oligomers only in the extracellular compartment.
These data suggest that lipidated apoE2, 3, or 4 supports oligomeric A␤ generation to different extents, and we hypothesized
that this was due to differences in their conformation (Jones et al.,
2011). apoE2 and apoE3 prefer an open conformation, whereas
apoE4 prefers a closed conformation due to a difference at amino
acid residue 112 between apoE4 (Arg) and apoE2, E3 (Cys)
(Dong et al., 1994; Mahley et al., 2009); indirectly this changes a
salt bridge and alters the domain– domain interactions of the
amino and carboxyl halves of apoE. To test the hypothesis that
the difference of the tertiary structure of apoE is responsible for
the observed isoform-dependent differences in apoE’s facilitation of oligomer formation, we examined the effects of the apoE4
R61T mutation, which is known to change the apoE4 conformation so that it mimics the closed apoE3 conformation (Ye et al.,
2005). We transiently transfected apoA-II, apoE3, apoE4, or
apoE4 R61T into doubly expressing HEK293 cells, collected conditioned media after 24 h incubation, and measured its luminescence in the media (Fig. 4 D). We found that apoE4 R61T
increased the level of A␤ oligomers to the same extent as apoE3,
but not as high as apoE4, suggesting that the tertiary structure of

Figure 4. ApoE enhanced the level of A␤ oligomers in an isoform-dependent manner. A,
Transient transfection of GFP (control), apoA-II, apoE2, apoE3, or apoE4 into double-expressing
HEK293 cells. Luminescence of conditioned media was measured. apoE3 significantly increased
the luminescence compared with apoE2 and apoE4 significantly increased the luminescence
compared with apoE3. N ⫽ 6, average ⫾ SD, *p ⬍ 0.05, one-way ANOVA test (Bonferroni’s
test). B, Immunoblotting of conditioned media from GFP (control), apoE2, apoE3, or apoE4
transiently transfected double-expressing HEK293 cells by an anti-apoE mAb 3H1. C, Transient
transfection of apoA-II, apoE2, apoE3, or apoE4 into double-expressing HEK293 cells. Luminescence of cell lysates was measured. There is no significant difference of the luminescence among
apoE2-, apoE3-, or apoE4-expressing cells. N ⫽ 6, average ⫾ SD, one-way ANOVA test (Bonferroni’s test). D, Transient transfection of apoA-II, apoE3, apoE4, or apoE4 R61T mutant into
double-expressing HEK293 cells. Luminescence of conditioned media was measured. apoE4
significantly increased the luminescence compared with apoE4 R61T mutant. N ⫽ 6, average ⫾ SD, *p ⬍ 0.05, one-way ANOVA test (Bonferroni’s test). E, Transient transfection of
apoE2, apoE3, or apoE4 into double-expressing HEK293 cells and separation of conditioned
media by a SEC column Superdex 200. Representative data of the luminescence profile of the
elutants from conditioned media of apoE2 (circles)-, apoE3 (triangles)-, or apoE4 (squares)transfected cells. Two peaks, HMW oligomers and dimers (arrows) were observed. F, Average
ratio between HMW oligomers and dimers. N ⫽ 3, average ⫾ SD, *p ⬍ 0.01, one-way ANOVA
test (Bonferroni’s test).

apoE is relevant to the apoE isoform-dependent effect on A␤
oligomerization (100.80 ⫾ 7.4% in apoA-II, 228.8 ⫾ 15.8% with
apoE3, 260.8 ⫾ 17.7% with apoE4, 228.4 ⫾ 10.9% with apoE4
R61T; p ⬍ 0.05, E4 vs E4 R61T). We did not see any difference in
the levels of apoE expression among apoE3, apoE4, and ApoE4
R61T.
We previously demonstrated that the split-luciferase-tagged
A␤ oligomers consist of HMW 24⬃36 mer and low-molecular
weight dimers by SEC analyses (Hashimoto et al., 2011). To evaluate whether apoE shifts the molecular size of A␤ oligomers, we
separated conditioned media from apoE2, apoE3, or apoE4 transiently transfected doubly expressing HEK293 cells using a single
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Superdex 200 SEC column, collected the eluted fractions, and
measured their luminescence (Fig. 4 E). We found that apoE4
significantly increased the level of HMW putative 24⬃36 mer
oligomers (or complexes of A␤ with other proteins) and decreased the level of dimers (Fig. 4 E, F, p ⬍ 0.01). We observed no
significant shift in the elution profile of A␤ oligomers by apoEs.
apoA-I and apoJ/clusterin also enhanced A␤ oligomerization
In addition to apoE, apoA-I, apoA-II, and apoJ/clusterin are also
present on the HDL particles in the brain. Recently, several
genome-wide association studies have identified a variant at CLU
(gene of apoJ/clusterin) to be associated with Alzheimer’s disease
(Harold et al., 2009; Lambert et al., 2009). It has also been reported that apoJ/clusterin-deficient mice crossed with APPtransgenic mice exhibit significantly fewer fibrillar A␤ deposits in
the brain compared with APP-transgenic mice (DeMattos et al.,
2002). Hence we asked whether these other apolipoproteins
might also modulate A␤ oligomerization. To address this question, we transiently transfected apoA-I, apoA-II, apoJ, and apoE3
into doubly expressing HEK293 cells, collected their conditioned
media after 24 h incubation, and measured their luminescence
(Fig. 5). Interestingly, apoA-I and apoJ/clusterin also enhanced
the luminescence, although to a lesser extent than apoE3, whereas
apoA-II did not change the luminescence from baseline (132.0 ⫾
7.0% in apoA-I, 89.3 ⫾ 6.6% in apoA-II, 163.5 ⫾ 12.1% in apoJ/
clusterin, 278.8 ⫾ 26.0% in apoE3, p ⬍ 0.05). This suggests that
apoA-I and apoJ/clusterin may also modulate the metabolism of
A␤ oligomers in the brain, and reinforces the idea that lipidated
particles supported by several apolipoproteins may act as a scaffold for A␤ interactions.
The lipid-binding domain of apoE is necessary for
enhancement of A␤ oligomerization
apoE has a receptor-binding domain in the N-terminal region
and a lipid-binding domain in the C-terminal region (Fig. 6 A;
Chou et al., 2005). To understand which domain of apoE is important in the enhancement of A␤ oligomerization, we expressed
the apoE NTFs (apoE2 NTF, apoE3 NTF, apoE4 NTF) or apoE
CTF in double-expressing HEK293 cells, collected conditioned
media after 24 h incubation and measured their luminescence
(Fig. 6 B, C). We found that apoE2 NTF, apoE3 NTF, or apo4
NTF did not enhance the luminescence, whereas apoE CTF significantly enhanced the luminescence to an extent similar to that
of full-length apoE3 (80.4 ⫾ 13.4% for apoE2 NTF, 103.1 ⫾ 9.2%
for apoE3 NTF, 104.5 ⫾ 8.6% for apoE4 NTF, compared with
175.5 ⫾ 22.6% for apoE CTF and 191.5 ⫾ 13.2% with full-length
apoE3; p ⬍ 0.05, apoE3 and apoE3 CTF; no significant difference,
apoE2 NTF, apoE3 NTF, and apoE4 NTF). This suggests that the
C-terminal region of apoE is necessary and sufficient to induce
A␤ oligomerization. We also coexpressed both apoE3 and apoE3
NTF together in doubly expressing HEK293 cells and found that
apoE3 NTF did not inhibit the enhancing effect of apoE3, suggesting that the N-terminal fragments of apoE is a loss-offunction molecule regarding A␤ oligomerization (Fig. 6 B,
166.9 ⫾ 19.2% in apoE3 and apoE3 NTF, p ⬍ 0.05). In immunoblotting, we confirmed the expression of these apoE fragments
using anti-human apoE antibodies. Mab 6C5, its epitope located
in the N-terminal region of apoE, recognized full-length apoE3,
apoE2 NTF, apoE3 NTF, and apoE4 NTF (Fig. 6 A, C). Mab 3H1
(epitope located at 243–272 aa residues of apoE), recognized fulllength apoE3 and apoE CTF (Fig. 6 A, C).
The C-terminal domain of apoE contains the major lipidbinding region (243–272 aa residues; Hatters et al., 2006; Mahley et

Figure 5. ApoA-I and apoJ enhanced the level of A␤ oligomers. Transient transfection of GFP
(control), apoA-I, apoA-II, apoJ/clusterin, or apoE3 into double-expressing HEK293 cells. Luminescence of conditioned media was measured. apoA-I, apoJ/clusterin, or apoE3 significantly
increased the luminescence. N ⫽ 6, average ⫾ SD, *p ⬍ 0.05, one-way ANOVA test (Bonferroni’s test).

al., 2009). To find the C-terminal domain of apoE responsible for the
enhancement of A␤ oligomerization, we next expressed apoE 231–
299, apoE 243–299, apoE192–272, and apoE 192–242 in A␤ splitluciferase-expressing HEK293 cells, collected conditioned media
after 24 h incubation, and measured the luminescence (Fig. 6D). We
found that apoE 231–299 and apoE 243–299 increased the luminescence to the same level as apoE CTF, whereas apoE 192–272 did not
increase the luminescence as strongly as apoE CTF. apoE 192–242
luminescence was even lower than that of apoE 192–272 (91.7 ⫾
3.9% in apoA-II, 274.4 ⫾ 24.4% in apoE3, 112.9 ⫾ 13.1% in apoE3
NTF, 239.0 ⫾ 7.6% in apoE CTF, 222.9 ⫾ 6.0% in apoE 231–299,
235.3 ⫾ 14.5% in apoE 243–299, 184.9 ⫾ 8.3% in apoE 192–272,
142.0 ⫾ 4.0% in apoE 192–242; p ⬍ 0.05, apoA-II vs apoE3, apoE
CTF, apoE 231–299, or apoE 243–299; apoE CTF vs apoE 192–272;
apoE 192–272 vs apoE 192–242). Together, these data suggest that
the 243–299 aa residues in the C-terminal region of apoE are especially important in the enhancement of A␤ oligomers. We confirmed similar expression levels of these apoE fragments by
immunoblotting using a goat anti-apoE polyclonal antibody and
mAb 3H1.
To further examine the effect of the 243–299 aa residues of
apoE in the enhancement of the A␤ oligomerization, we also
expressed the deletion mutants, apoE3 ⌬243–272, apoE3 ⌬273–
299, and apoE3 ⌬243–299, collected culture media after 24 h
incubation, and measured their luminescence (Fig. 6 E). We
found that apoE3 ⌬243–272, apoE3 ⌬273–299, and apoE3 ⌬243–
299 significantly decreased the level of luminescence compared
with full-length apoE3 and that apoE3 ⌬243–299 significantly
decreased the luminescence compared with apoE3 ⌬273–299
(218.1 ⫾ 19.7% in apoE3, 114.0 ⫾ 7.1% in apoE3 NTF, 205.9 ⫾
7.2% in apoE CTF, 154.4 ⫾ 6.8% in apoE3 ⌬243–272, 176.8 ⫾
13.5% in apoE3 ⌬273–299, 143.8 ⫾ 10.0% in apoE3 ⌬243–299;
p ⬍ 0.01, apoA-II vs apoE3 or apoE CTF; p ⬍ 0.05, apoE3 vs
apoE3 ⌬243–272, apoE3 ⌬273–299, or apoE3 ⌬243–299; apoE3
⌬273–299 vs apoE3 ⌬243–272 or apoE3 ⌬243–299). We confirmed similar expression levels of these apoE mutants by immunoblotting using mAb 6C5 and mAb 3H1. Together, these results
strongly argue that the C-terminal region of apoE, especially a
domain within amino-acid residues 243–272, is essential for
apoE’s support of A␤ oligomers. This domain is the major lipidbinding domain of apoE; thus, the lipidation of apoE may be
crucial in the enhancement of A␤ oligomerization, as this region
may act to help catalyze oligomer formation.
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extract of human brain by SEC and found both apoE and HMW A␤ oligomers
are eluted into fraction 7 and 8 (Fig. 2 B).
We first incubated SEC-separated TBSsoluble fractions 6 –9 from AD APOE
3/3 brains, AD APOE 4/4 brains (Fig.
7A), or control brains (Fig. 7B) with conditioned media from doubly expressing
HEK293 cells for 24 h at 37°C, and measured the luminescence. We observed that
all four fractions, but especially fraction 8
from both AD and control brains, increased the luminescence (141.8% in AD
fraction 6, 198.4% in AD fraction 7,
256.4% in AD fraction 8, 207.6% in AD
fraction 9, 99.8% in control fraction 6,
163.2% in control fraction 7, 230.8% in
control fraction 8, 202.6% in control fraction 9). We also found that apoE eluted in
fraction 8 from AD and control brain by
immunoblotting using a goat anti-apoE
antibody (Fig. 7 A, B, bottom). Next, to
test the hypothesis that apoE mediated the
increase in luminescence observed due to
fraction 8, we immunodepleted apoE
from fraction 8 using an anti-human apoE
mAb 3H1, incubated with conditioned
media from doubly expressing HEK293
cells for 24 h at 37°C, and measured the
luminescence (Fig. 7C). We found that
apoE-immunodepleted sample significantly decreased the level of luminescence
compared with immunodepletion using a
control antibody (261.8 ⫾ 47.3% with no
antibody, 168.1 ⫾ 44.6% with anti-apoE
antibody, 237.1 ⫾ 24.5% with control antibody, p ⬍ 0.05). Moreover, it is these
fractions that were used for the immunoprecipitation of apoE and A␤ described
above (Fig. 2C). Finally, we incubated
fraction 8 from 4 AD patients with the
Figure 6. Lipid-binding domain of apoE was necessary for the enhancement of A␤ oligomers. A, Schematic structure of APOE 4/4 genotype and 4 AD patients
apoE and apoE fragments. The epitopes of mAb 6C5 and mAb 3H1 is illustrated. B, Transient transfection of GFP, apoE3, with the APOE 3/3 genotype with conapoE2 NTF, apoE3 NTF, apoE4 NTF, apoE CTF, or both apoE3 and apoE3 NTF into double-expressing HEK293 cells. Lumines- ditioned media from doubly expressing
cence of conditioned media was measured. apoE3 and apoE CTF significantly increased the luminescence, on the other HEK293 cells for 24 h at 37°C, and meahand, apoE2 NTF, apoE3 NTF, or apoE4 NTF did not increase the luminescence. N ⫽ 6, average ⫾ SD, *p ⬍ 0.05, one-way
sured the luminescence (Fig. 7D). We obANOVA test (Bonferroni’s test). C, Immunoblotting of conditioned media by the anti-apoE mAb 6C5 (top) and 3H1 (bottom
served that fractions from APOE 4/4
panel). MAb 6C5 revealed 36 kDa band (full-length apoE, arrowhead) and 26 kDa band (apoE NTF, arrow). MAb 3H1
revealed also 36 kDa band (full-length apoE, arrowhead) and 10 kDa doublet band (apoE CTF, arrow). D, Transient AD patients led to significantly increased
transfection of GFP, apoA-II, apoE3, apoE3 NTF, apoE CTF, apoE 231–299, apoE 243–299, apoE 192–272, and apoE levels of A␤ oligomers compared with that
192–242 into double-expressing HEK293 cells. Luminescence of conditioned media was measured. apoE3 significantly from APOE 3/3 AD patients (193.0 ⫾
increased the luminescence compared with apoA-II, apoE CTF fragments. apoE CTF significantly increased the luminescence 4.9% in APOE 4/4 AD patients and
compared with apoE 192–272 and apoE 192–272 significantly increased the luminescence compared with apoE 192–242. 167.6 ⫾ 6.8% in APOE 3/3 AD patients,
N ⫽ 6, average ⫾ SD, *p ⬍ 0.05, one-way ANOVA test (Bonferroni’s test). E, Transient transfection of GFP, apoA-II, apoE3, p ⬍ 0.05). These data indicate that endogapoE3 NTF, apoE CTF, apoE3 ⌬243–272, apoE3 ⌬273–299, and apoE3 ⌬243–299 into double-expressing HEK293 cells. enous apoE from human brain increased
Luminescence of conditioned media was measured. apoE3 and apoE CTF significantly increased the luminescence com- the level of A␤ oligomers, supporting the
pared with apoA-II. ApoE3 also significantly increased the luminescence compared with three apoE3 deletion mutants.
hypothesis that lipidated apoE derived
ApoE3 ⌬273–299 significantly increased the luminescence compared with apoE3 ⌬243–272 or apoE3 ⌬243–299. N ⫽ 6,
from human brain also enhances A␤ oliaverage ⫾ SD, *p ⬍ 0.01, **p ⬍ 0.05, one-way ANOVA test (Bonferroni’s test).
gomerization. The residual enhancement
of luminescence after immunodepletion
Human brain apoE promoted A␤ oligomerization
might be due to incomplete immunodepletion, the preservation
Since lipidated apoE particles generated in culture enhanced A␤
of lipidated particles that do not contain apoE, or other non-apoE
oligomerization, we next tested whether apoE isolated from hufactors (including oligomeric A␤ itself) that might act as a nidus
man brain might have the same effect. We separated the TBSfor oligomer formation.
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Figure 7. Endogenous apoE in the brain increases the level of A␤ oligomers. A, B, Luminescence of SEC-separated fraction 6, 7, 8, or 9 from TBS-soluble fraction of AD (A) or control (B)
brain incubated with split-luciferase-tagged A␤ oligomers for 24 h. An anti-apoE antibody
revealed 36 kDa apoE protein (bottom). C, Immunodepletion of fraction 8 of AD brains using no
antibody, anti-apoE mAb 3H1 or control Ig. Luminescence from immunodepleted fraction 8 of
AD brains incubated with split-luciferase-tagged A␤ oligomers for 24 h. Anti-apoE mAb 3H1
significantly reduced the luminescence compared with control Ig. N ⫽ 4, average ⫾ SD, *p ⬍
0.05, one-way ANOVA test (Bonferroni’s test). D, Luminescence of SEC-separated fraction 8
from TBS-soluble fraction of 4 APOE 4/4 AD brains and 4 APOE 3/3 AD brains incubated
with split-luciferase-tagged A␤ oligomers for 24 h. Fraction 8 from APOE 4/4 AD brains
significantly increased the level of A␤ oligomers compared with that APOE 3/3 AD brains.
Average ⫾ SD, *p ⬍ 0.05, one-way ANOVA test (Bonferroni’s test).

Discussion

In this study, we demonstrate that the levels of A␤ oligomers in
TBS-soluble fraction of AD APOE 4/4 brains are 2.7-fold
higher compared with APOE 3/3 patient brains and 6.9-fold
higher compared with APOE 2/x patient brains, whereas brains
from non-demented controls had negligible levels of A␤ oligomers (Fig. 1 A, B). We also found that A␤ and apoE coeluted into
HMW fractions in SEC-separated TBS-soluble fraction from AD
brains, and coimmunoprecipitated (Fig. 2 B, C), suggesting the
possibility of an in vivo interaction between them. We confirmed
that A␤ and apoE coeluted into HMW fractions in SEC-separated
interstitial fluid from APP-PS mouse brains using a microdialysis
techniques with a 1000 kDa molecular weight cutoff membrane
probe (S. Takeda, T. Hashimoto, and B. T. Hyman, unpublished
observation), suggesting that the apoE and A␤ HMW complex
endogenously exists in the brain and is not a product caused
during the mechanical homogenization steps.
Based on these data, we hypothesized that apoE would facilitate A␤ oligomerization, and tested the idea that the extent of
oligomer formation would be isoform dependent. We performed
A␤ oligomerization assays using three different preparations of
apoE. First, apoE on HDL particles, purified from conditioned
media of immortalized astrocytes expressing human apoE2, apoE3,
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or apoE4, promoted the oligomerization of synthetic A␤, splitluciferase-tagged A␤ oligomers, or LMW A␤ isolated from TBS-soluble
fraction of AD patients’ brains A␤ (Fig. 3). Second, transient overexpression of apoE2, apoE3, or apoE4 in HEK293 cells stably expressing split-luciferase-tagged A␤ oligomers increased A␤ oligomers
through apoE’s C-terminal domain in an isoform-dependent manner (apoE2 ⬍ apoE3 ⬍ apoE4; Figs. 4, 6). Third, endogenous apoE
extracted from TBS-soluble fraction of human AD and control
brains also increased A␤ oligomers, again apoE3 ⬍ apoE4 (Fig. 7).
Similarly, we assessed oligomerization using two preparations: synthetic A␤ and a quantitative split-luciferase assay, with confirmatory
results. apoE, especially apoE4, appears to enhance A␤ oligomers.
The current view of AD pathophysiology emphasizes the deleterious effects of A␤ oligomers on synapses, leading to synaptic
dysfunction, and progressive memory impairment in AD patients (Lesné et al., 2006; Shankar et al., 2008; Li et al., 2009; Wu et
al., 2010). Recently we found that apoE colocalized with A␤ oligomers at synapse in the brain of AD patient brains using an array
tomographic technique and found that APOE 4/4 AD patients
have a significantly higher level of colocalization of apoE and A␤
oligomers at synapse compared with APOE 3/3 AD patients
(Koffie et al., 2012). Our results suggest that apoE4 increases the
level of A␤ oligomers in the brain, leading to increased synaptic
localization with A␤ oligomers, synaptic dysfunction, and hastening the development of cognitive impairments.
Biochemical analyses of human AD revealed that the level of
TBS-soluble A␤ oligomers in APOE 4/4 brains are 2.7-fold
higher compared with AD APOE 3/3 brains and 6.9-fold
higher compared with AD APOE 2/x brains (Fig. 1 A, B). Importantly, these AD groups were matched for deposited amyloid
burden. No significant correlation was observed between plaque
burden and levels of TBS-soluble A␤ oligomers (r ⫽ ⫺0.01, p ⫽
0.95, Spearman’s rank correlation test), so that the 2.7-fold difference in the levels of TBS-soluble A␤ oligomers between them
cannot be attributed to the disruption of a higher amount of
senile plaques in the APOE 4/4 group during the homogenization of the specimens. Thus, these results indicate that apoE influences both plaque burden and also the levels of TBS-soluble
A␤ oligomers in an isoform-differential manner.
Using both synthetic A␤ (Fig. 3A) and a split-luciferase complementation assay (Figs. 3C, 4), we found that apoE increased
A␤ oligomerization in an isoform-dependent manner (apoE2 ⬍
apoE3 ⬍ apoE4). Interestingly, experiments using deletion mutants of apoE demonstrate that the C-terminal domain of apoE is
necessary and sufficient to drive A␤ oligomerization, suggesting
that apoE may directly interact with A␤ oligomers through its
C-terminal region (Fig. 6 B, D,E). We also found that apoE4 enhanced the ratio of HMW A␤ oligomers compared with apoE2 or
apoE3 (Fig. 4 E, F ), suggesting that N-terminal domain might be
important to modulate A␤ oligomerization. In a recent study
using the anti-apoE mAb 3H1, which recognizes the amino acids
243–272, we observed significantly higher levels of apoE
C-terminal fragments in APOE 4/4 AD brains compared with
APOE 3/3 AD brains. In addition, using in situ fluorescence
lifetime imaging–fluorescent resonance energy transfer in human AD brain specimens, we found that A␤ is closer to the apoE
C-terminal region than to its N-terminal region within doubly
labeled senile plaques (Jones et al., 2011). Together, these results
argue that not only full-length apoE4 but also C-terminal fragments of apoE4 containing the region at 243–272 amino-acid
residues may additionally enhance the formation of A␤ oligomers in APOE 4/4 brains. Interestingly, the 243–272 aa residues
of apoE are the major lipid-binding region of apoE, supporting
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the idea that apoE lipidation may be critical to facilitate A␤ oligomer formation. We hypothesize that lipidated apoE might
concentrate A␤ monomer and provide a scaffold for oligomerization of A␤. Alternatively, we found lipidated apoE4 increased
the level of synthetic A␤ trimers and tetramers (Fig. 3B), suggesting that lipidated apoE, especially apoE4, might stabilize A␤ oligomers and inhibit the dissociation or further aggregation of A␤.
Furthermore, A␤ oligomers may be able to escape from A␤ degradation or phagocytosis by binding to apoE on HDL particles.
In addition to apoE, we found apoJ/clusterin and apoA-I,
other apolipoproteins on the HDL particles, increased the level of
A␤ oligomers (Fig. 5). Common variants in the apoJ/clusterin
gene (CLU ) have recently been linked to an increased risk of
developing AD (Harold et al., 2009; Lambert et al., 2009), and
apoJ/clusterin-deficient mice crossed with APP-transgenic mice
exhibit significantly fewer fibrillar A␤ deposits in the brain compared with APP-transgenic mice (DeMattos et al., 2002), suggesting that apoJ/clusterin may modify A␤ oligomer formation in the
human brain similarly to apoE. By contrast, crossing apoA-Ideficient mice with APP-transgenic mice did not alter A␤ deposition in the brain (Fagan et al., 2004), indicating a small or no
effect of apoA-I on A␤ oligomerization and fibrillization. We
observed that apoA-I only slightly increased the levels of A␤ oligomers (Fig. 5).
Recently, it was reported that the level of soluble oligomeric
A␤ in frontal cortex of young adults is higher than that of
elderly people or Alzheimer’ disease patients using ELISA experiments (van Helmond et al., 2010), potentially calling into
question a relationship between oligomeric A␤ (as measured
by the ELISA) with Alzheimer disease pathogenesis. In this
study we observed that the level of HMW A␤ from TBSsoluble fraction is under-estimated in ELISA experiments due
to a possible masking effect either by itself or interacting molecules, and the treatment with 8 M Guanidine-HCl increases
the measured concentration of A␤ in HMW A␤ fractions using our specific ELISA conditions (Fig. 2 A). It would be interesting to evaluate the age-dependent ELISA results in the
context of these technical issues of A␤ measurement.
In summary, we provide in vivo and in vitro evidence that
apoE interacts with A␤ oligomers through its C-terminal region
and that apoE, particularly apoE4, promotes and stabilizes A␤
oligomerization. Given the relatively large magnitude of these
effects (e.g., a 2.7-fold increase in A␤ oligomers in APOE 4/4
Alzheimer brains, compared with APOE E3/3 Alzheimer brains),
it is plausible that these observations help explain the major risk
for AD associated with APOE 4 inheritance. Both the inhibition
of the interaction between apoE and A␤ oligomers and the inhibition of the lipidation of apoE may be valuable therapeutic targets to prevent A␤ oligomerization and subsequent synaptic
dysfunction.
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